{"id":47223,"date":"2022-08-12T01:02:08","date_gmt":"2022-08-11T23:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/taro-pharmaceuticals-inc-issues-voluntary-type-i-recall-of-taro-zoledronic-acid-injection-5-mg-100-ml-100-ml-vial-due-to-particulate-matter-over-specified-requirements\/"},"modified":"2022-08-12T01:02:08","modified_gmt":"2022-08-11T23:02:08","slug":"taro-pharmaceuticals-inc-issues-voluntary-type-i-recall-of-taro-zoledronic-acid-injection-5-mg-100-ml-100-ml-vial-due-to-particulate-matter-over-specified-requirements","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/taro-pharmaceuticals-inc-issues-voluntary-type-i-recall-of-taro-zoledronic-acid-injection-5-mg-100-ml-100-ml-vial-due-to-particulate-matter-over-specified-requirements\/","title":{"rendered":"Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg\/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements"},"content":{"rendered":"
\n

BRAMPTON, Ontario–(BUSINESS WIRE)–Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg\/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements. This recall is being conducted with the knowledge of Health Canada.\n<\/p>\n

\nThe presence of foreign particulate matter in vials of the affected lots could potentially cause unintended adverse events. Taro has received no reports<\/b> of<\/b> serious adverse events<\/b> associated with this product.\n<\/p>\n

\nThe impacted lots are listed below.\n<\/p>\n\n\n\n\n\n\n\n\n
\n

\nSr. No<\/b>\n<\/p>\n<\/td>\n

\n

\nBatch No.<\/b>\n<\/p>\n<\/td>\n

\n

\nExpiry. Date<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n1<\/b>\n<\/p>\n<\/td>\n

\n

\nJKX1910A\n<\/p>\n<\/td>\n

\n

\nApril-2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2<\/b>\n<\/p>\n<\/td>\n

\n

\nJKX4318A\n<\/p>\n<\/td>\n

\n

\nAug-2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n3<\/b>\n<\/p>\n<\/td>\n

\n

\nJKX5541A\n<\/p>\n<\/td>\n

\n

\nNov-2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n4<\/b>\n<\/p>\n<\/td>\n

\n

\nHAC2371A\n<\/p>\n<\/td>\n

\n

\nJun-2024\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n5<\/b>\n<\/p>\n<\/td>\n

\n

\nHAC4421A\n<\/p>\n<\/td>\n

\n

\nNov-2024\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n6<\/b>\n<\/p>\n<\/td>\n

\n

\nHAD0156A\n<\/p>\n<\/td>\n

\n

\nJan-2025\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTaro-Zoledronic Acid Injection, 5 mg\/100 mL is used to increase bone mineral density, to treat and prevent osteoporosis as well as to treat Paget\u2019s disease (a condition that causes bone deformities).\n<\/p>\n

\nConsumers in possession of Taro-Zoledronic Acid Injection should check to see if the product is one of the six (6) referenced lots listed above and, if so, return the drug to their pharmacy.\n<\/p>\n

\nTo report a suspected adverse event related to Taro-Zoledronic Acid Injection, please contact Taro\u2019s Medication Information line at 1-866-877-5180 or by email at PVCanada@taro.com<\/a>.\n<\/p>\n

\nPatients may also report any suspected adverse reaction associated with the use of health products to Health Canada by:\n<\/p>\n